SCHEMBL311935

SCHEMBL311935

O=C(O)c1cn(C2CC2)c2nc(N3CCNCC3)c(F)cc2c1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.68
CYP2C9 P11712 2/20 0.68
ATP6V1B2 P21281 1/20 0.68
TBXA2R P21731 1/20 0.68
EDNRA P25101 1/20 0.68
TARBP2 Q15633 1/20 0.68
KDM4E B2RXH2 4/20 0.65
HSD17B10 Q99714 3/20 0.65
ALDH1A1 P00352 3/20 0.65
HPGD P15428 2/20 0.65
TOP2A P11388 2/20 0.65
TOP2B Q02880 2/20 0.65
CYP1A2 P05177 1/20 0.65
DPP4 P27487 6/20 0.62
CHRM2 P08172 1/20 0.57
DRD1 P21728 1/20 0.57
DHFR P00374 1/20 0.54
ABCC4 O15439 1/20 0.53
KMT2A Q03164 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11020192 0.96 LMNA (0.64) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10377708 0.90 DPP4 (0.66) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10377337 0.89 DPP4 (0.65) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10377719 0.89 DPP4 (0.65) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL11022634 0.88 DPP4 (0.68) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9686951 0.88 KDM4E (0.54) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10377364 0.88 DPP4 (0.62) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10377621 0.88 DPP4 (0.62) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10377610 0.88 DPP4 (0.62) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9687753 0.87 KDM4E (0.63) LMNACYP2C9ATP6V1B2TBXA2REDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0153828-B1 1-CYCLOPROPYL-1, 4-DIHYDRO-6-FLUORO-4-OXO-1, 8-NAPHTHYRIDINE-3-CARBOXYLIC ACIDS; THEIR DERIVATIVES AND A PROCESS FOR PREPARING THE COMPOUNDS WARNER-LAMBERT COMPANY (US) 1990-12-27 EP claimed
CN-1003236-B Preparation method of 6, 7-disubstituted-1-cyclopropyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid 拜尔公司 1989-02-08 CN claimed
JP-60197686-A None JP disclosed
JP-60032790-A None JP disclosed
WO-2017133517-A1 PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF 四川海思科制药有限公司 2017-08-10 WO disclosed
EP-1730154-B1 RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES CUMBRE IP VENTURES L P (US) 2012-10-17 EP disclosed
US-8093381-B2 Method of synthesis of fluoroquinolones BIOCODEX (FR) 2012-01-10 US disclosed
EP-2138490-B1 New method for synthesis of fluoroquinolones BIOCODEX (FR) 2011-08-31 EP disclosed
US-20090054643-A1 NOVEL METHOD OF SYNTHESIS OF FLUOROQUINOLONES BIOCODEX (FR) 2009-02-26 US disclosed
US-7247634-B2 Rifamycin derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS INC. (US) 2007-07-24 US disclosed
US-7238694-B2 Rifamycin imino derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
CN-86100126-A 6, the two replacement-1-cyclopropyl of 7--1,4 dihydro-4-oxo-1, the preparation method and the application thereof of 8-naphthyridines-3-carboxylic acid 1986-07-09 CN disclosed
EP-0172651-A1 Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds WARNER-LAMBERT COMPANY (US) 1986-02-26 EP disclosed
US-4571396-A Antibacterial agents WARNER-LAMBERT COMPANY (US) 1986-02-18 US disclosed
EP-0160578-A1 1,8-Naphthyridine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1985-11-06 EP disclosed
EP-0159174-A2 Substituted naphthyridine-, quinoline- and benzoxazine- carboxylic acids as antibacterial agents and processes for their production WARNER-LAMBERT COMPANY (US) 1985-10-23 EP disclosed
JP-S60197686-A 1,8-NAPHTHYRIDINE DERIVATIVE DAI ICHI SEIYAKU CO LTD 1985-10-07 JP disclosed
EP-0153828-A2 1-cyclopropyl-1, 4-dihydro-6-fluoro-4-oxo-1, 8-naphthyridine-3-carboxylic acids; their derivatives and a process for preparing the compounds WARNER-LAMBERT COMPANY (US) 1985-09-04 EP disclosed
EP-0153163-A2 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds WARNER-LAMBERT COMPANY (US) 1985-08-28 EP disclosed
JP-S6032790-A 1,8-NAPHTHYRIDINES DAINIPPON PHARMACEUT CO LTD 1985-02-19 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054643-A1 NOVEL METHOD OF SYNTHESIS OF FLUOROQUINOLONES NQO2, Q6ZSR9, QARS1 LMNA 2081/4885CYP2C9 109/4885ATP6V1B2 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.